![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2020
Stintzing, Sebastian; Oostrum, Ilse van; Pescott, Chris P.; Ronga, Philippe; Heeg, Bart und Heinemann, Volker
(2020):
Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.
In: Journal of Medical Economics, Bd. 23, Nr. 5: S. 448-455
2019
Aly, Markus; Hashim, Mahmoud; Heeg, Bart; Liwing, Johan; Leval, Amy; Mehra, Maneesha; Lawson, Joe; Brookman-May, Sabine D. und Akre, Olof
(2019):
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data.
In: European Urology Focus, Bd. 5, Nr. 5: S. 788-798
2009
Treur, Maarten; Heeg, Bart; Moeller, Hans-Juergen; Schmeding, Annette und van Hout, Ben
(2009):
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
In: BMC Health Services Research
9:32
[PDF, 257kB]